File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cardiac tissue engineering using human stem cell-derived cardiomyocytes for disease modeling and drug discovery

TitleCardiac tissue engineering using human stem cell-derived cardiomyocytes for disease modeling and drug discovery
Authors
Issue Date2012
PublisherElsevier Ltd, Trends Journals. The Journal's web site is located at http://www.elsevier.com/locate/ddmod
Citation
Drug Discovery Today: Disease Models, 2012, v. 9 n. 4, p. e219-e227 How to Cite?
AbstractCardiovascular disease (CVD) is the most prevalent health problem in the world, and the high mortality rate associated with irreversibly injured heart muscle motivates an urgent need for the development of novel therapies to treat damaged myocardium. Recently, human engineered cardiac tissues (hECT) have been created using cardiomyocytes (CM) derived from human embryonic stem cells (hESC) and human induced pluripotent stem cells (hiPSC). Although a healthy adult phenotype remains elusive, such hECT display structural and functional properties that recapitulate key aspects of natural human myocardium, including dose related responses to compounds with known chronotropic, inotropic and arrhythmogenic effects. Thus, hECT offer the advantage over traditional in vitro culture models of providing a biomimetic 3D environment for the study of myocardial physiopathology, and may be used to generate preclinical models for the development and screening of therapies for CVD. © 2012 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/143052
ISSN
2015 SCImago Journal Rankings: 0.286

 

DC FieldValueLanguage
dc.contributor.authorTurnbull, ICen_US
dc.contributor.authorLieu, DKen_US
dc.contributor.authorLi, RA-
dc.contributor.authorCosta, K-
dc.date.accessioned2011-10-28T03:05:26Z-
dc.date.available2011-10-28T03:05:26Z-
dc.date.issued2012en_US
dc.identifier.citationDrug Discovery Today: Disease Models, 2012, v. 9 n. 4, p. e219-e227-
dc.identifier.issn1740-6757-
dc.identifier.urihttp://hdl.handle.net/10722/143052-
dc.description.abstractCardiovascular disease (CVD) is the most prevalent health problem in the world, and the high mortality rate associated with irreversibly injured heart muscle motivates an urgent need for the development of novel therapies to treat damaged myocardium. Recently, human engineered cardiac tissues (hECT) have been created using cardiomyocytes (CM) derived from human embryonic stem cells (hESC) and human induced pluripotent stem cells (hiPSC). Although a healthy adult phenotype remains elusive, such hECT display structural and functional properties that recapitulate key aspects of natural human myocardium, including dose related responses to compounds with known chronotropic, inotropic and arrhythmogenic effects. Thus, hECT offer the advantage over traditional in vitro culture models of providing a biomimetic 3D environment for the study of myocardial physiopathology, and may be used to generate preclinical models for the development and screening of therapies for CVD. © 2012 Elsevier Ltd. All rights reserved.-
dc.languageengen_US
dc.publisherElsevier Ltd, Trends Journals. The Journal's web site is located at http://www.elsevier.com/locate/ddmoden_US
dc.relation.ispartofDrug Discovery Today: Disease Models-
dc.titleCardiac tissue engineering using human stem cell-derived cardiomyocytes for disease modeling and drug discoveryen_US
dc.typeArticleen_US
dc.identifier.emailLi, RA: ronaldli@hkucc.hku.hken_US
dc.identifier.authorityLi, RA=rp01352en_US
dc.identifier.doi10.1016/j.ddmod.2012.11.001-
dc.identifier.scopuseid_2-s2.0-84876675545-
dc.identifier.hkuros197128en_US
dc.identifier.volume9-
dc.identifier.issue4-
dc.identifier.spagee219-
dc.identifier.epagee227-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats